Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob Djavan

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
European Urology|January 19, 2008
New treatment approaches for prostate cancer based on peptide analoguesAnton Stangelberger, Andrew V Schally, Bob Djavan
Current Opinion in Urology|November 4, 2010
An algorithm for medical management in male lower urinary tract symptomsBob Djavan, Markus Margreiter, Seyed Saeid Dianat
Expert Opinion on Pharmacotherapy|September 22, 2010
Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasiaBob Djavan, Markus Johannes Handl, Saeid Dianat
Expert Opinion on Pharmacotherapy|March 11, 2005
Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasiaBob Djavan, Shirin Milani, Yan Kit Fong
The New England Journal of Medicine|December 31, 2005
Autoantibodies in prostate cancerBernardo Rocco, Bob Djavan, Ottavio de Cobelli
Reviews in Urology|September 21, 2006
Chemopreventive trials in urologic cancerVahagn R Ashughyan, Sibylle Marihart, Bob Djavan
Drugs of Today (Barcelona, Spain : 1998)|February 13, 2003
The pathophysiology of benign prostatic hyperplasiaBob Djavan, Mesut Remzi, Beate Erne, et al.
Current Opinion in Urology|April 20, 2004
Benign prostatic hyperplasia progression and its impact on treatmentBob Djavan, Matthias Waldert, Clemens Ghawidel, et al.
European Urology|May 28, 2003
Artificial neural networks for decision-making in urologic oncologyTheodore Anagnostou, Mesut Remzi, Michael Lykourinas, et al.
Urology|December 15, 2004
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaBob Djavan, Chris Chapple, Shirin Milani, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
European Urology|January 19, 2008
New treatment approaches for prostate cancer based on peptide analoguesAnton Stangelberger, Andrew V Schally, Bob Djavan
Current Opinion in Urology|November 4, 2010
An algorithm for medical management in male lower urinary tract symptomsBob Djavan, Markus Margreiter, Seyed Saeid Dianat
Expert Opinion on Pharmacotherapy|September 22, 2010
Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasiaBob Djavan, Markus Johannes Handl, Saeid Dianat
Expert Opinion on Pharmacotherapy|March 11, 2005
Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasiaBob Djavan, Shirin Milani, Yan Kit Fong
The New England Journal of Medicine|December 31, 2005
Autoantibodies in prostate cancerBernardo Rocco, Bob Djavan, Ottavio de Cobelli
Reviews in Urology|September 21, 2006
Chemopreventive trials in urologic cancerVahagn R Ashughyan, Sibylle Marihart, Bob Djavan
Drugs of Today (Barcelona, Spain : 1998)|February 13, 2003
The pathophysiology of benign prostatic hyperplasiaBob Djavan, Mesut Remzi, Beate Erne, et al.
Current Opinion in Urology|April 20, 2004
Benign prostatic hyperplasia progression and its impact on treatmentBob Djavan, Matthias Waldert, Clemens Ghawidel, et al.
European Urology|May 28, 2003
Artificial neural networks for decision-making in urologic oncologyTheodore Anagnostou, Mesut Remzi, Michael Lykourinas, et al.
Urology|December 15, 2004
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaBob Djavan, Chris Chapple, Shirin Milani, et al.
Pageof 12